Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection in patients with female pattern hair loss: a prospective cohort study. (3rd October 2021)

• Record Type: Journal Article
• Authors: Moftah, Nayera; Mubarak, Rana; Abdelghani, Rania
• Is Part Of: Journal of dermatological treatment. Volume 32:Number 7(2021)
• Page Start: 827
• Page End: 836
• Publication Date: 2021-10-03
• Subjects: Metabolic syndrome -- hair loss -- dutasteride -- trichoscope; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2019.1708849
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Background: No studies investigating the impact of metabolic syndrome (MetS) in treatment response of female pattern hair loss (FPHL). Objective: In this prospective cohort study, we studied the impact of MetS in response to intradermal dutasteride 0.02% injection in patients with FPHL. Methods: Fifty-one adult participants with FPHL were classified into study cohorts: with MetS and comparison cohorts without MetS. Both groups underwent clinical, trichoschopic, and digital folliscopic evaluation. Treatment was scheduled over a period of 3 months as four weekly sessions, followed by another four bimonthly sessions. Response was evaluated by digital folliscopy, investigator's, and patient's self assessments at 1 and 3 months post-treatment. Side effects were evaluated. Results: In participants with MetS, there was a significant reduction of the mean percentage of terminal hair with significant increase of the mean percentage of vellus hair ( p = .003, .006, respectively) compared with participants without MetS at 1 month after treatment. These significant differences persisted at 3 months after treatment; for terminal and vellus hair ( p = .000) with significant reduction in the mean hair thickness ( p = .002) compared with participants without MetS. Conclusions: MetS negatively impacted FPHL in terms of response to intradermal injection of dutasteride 0.02% and severity. Further studies are still needed.